Erratum: Promoting quality and evidence-based care in early-stage breast cancer follow-up (Journal of the National Cancer Institute (2014) 106:4 (dju034) DOI: 10.1093/jnci/dju034);Promoting quality and evidence-based care in early-stage breast cancer follow-up

Journal of the National Cancer Institute

Volumn 106, Issue 4, 2014, Pages

  Henry, Lynn N ^a   Hayes, Daniel F ^a   Ramsey, Scott D ^b   Hortobagyi, Gabriel N ^c   Barlow, William E ^d   Gralow, Julie R ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; TUMOR MARKER;

BLOOD ANALYSIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SCREENING; CANCER SURVIVAL; CANCER THERAPY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST; DRUG SURVEILLANCE PROGRAM; EARLY CANCER; EVIDENCE BASED PRACTICE; FALSE POSITIVE RESULT; FOLLOW UP; HEALTH CARE SYSTEM; HEALTH PROMOTION; HUMAN; MAMMOGRAPHY; METASTASIS; NEOPLASM; ONCOLOGIST; PATIENT MONITORING; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION HAZARD; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; SERUM; TECHNOLOGY; BLOOD; BREAST TUMOR; CANCER STAGING; EARLY DIAGNOSIS; EUROPE; EVIDENCE BASED MEDICINE; FEMALE; HEALTH CARE QUALITY; HEALTH SURVEY; LABORATORY DIAGNOSIS; METHODOLOGY; PATHOLOGY; TIME; TUMOR RECURRENCE; UNITED STATES;

BREAST NEOPLASMS; EARLY DETECTION OF CANCER; EUROPE; EVIDENCE-BASED MEDICINE; FALSE POSITIVE REACTIONS; FEMALE; GUIDELINE ADHERENCE; HUMANS; MAMMOGRAPHY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POPULATION SURVEILLANCE; PRACTICE GUIDELINES AS TOPIC; QUALITY OF HEALTH CARE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 84898863103     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju126     Document Type: Erratum

References (47)

1. Brody H. Medicine's ethical responsibility for health care reform-the top five list. N Engl J Med. 2010;362(4):283-285.
2. Schnipper LE, Smith TJ, Raghavan D, et al. American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol. 2012;30(14):1715-1724.
3. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25(33):5287-5312.
4. Khatcheressian JL, Hurley P, Bantug E, et al. Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology Clinical Practice Guideline update. J Clin Oncol. 2013;31(7):961-965.
5. Hensley ML, Dowell J, Herndon JE 2nd, et al. Economic outcomes of breast cancer survivorship: CALGB study 79804. Breast Cancer Res Treat. 2005;91(2):153-161.
6. Keating NL, Landrum MB, Guadagnoli E, Winer E P, Ayanian JZ. Surveillance testing among survivors of early-stage breast cancer. J Clin Oncol. 2007;25(9):1074-1081.
7. Foster JA, Abdolrasulnia M, Doroodchi H, McClure J, Casebeer L. Practice patterns and guideline adherence of medical oncologists in managing patients with early breast cancer. J Natl Compr Canc Netw. 2009;7(7):697-706.
8. Carlson RW, Allred DC, Anderson BO, et al. Invasive breast cancer. J Natl Compr Canc Netw. 2011;9(2):136-222.
9. Grunfeld E, Dhesy-Thind S, Levine M. Clinical practice guidelines for the care and treatment of breast cancer: follow-up after treatment for breast cancer (summary of the 2005 update). CMAJ. 2005;172(10):1319-1320.
10. Rojas M P, Telaro E, Russo A, et al. Follow-up strategies for women treated for early breast cancer. Cochrane Database Syst Rev. 2005;2005(1):CD001768.
11. GIVIO Investigators. Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. JAMA. 1994;271(20):1587-1592.
12. Rosselli Del Turco M, Palli D, Cariddi A, et al. Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow-up. JAMA. 1994;271(20):1593- 1597.
13. Palli D, Russo A, Saieva C, et al. Intensive vs clinical follow-up after treatment of primary breast cancer: 10-year update of a randomized trial. National Research Council Project on Breast Cancer Follow-up. JAMA. 1999;281(17):1586.
14. Kokko R, Hakama M, Holli K. Follow-up cost of breast cancer patients with localized disease after primary treatment: a randomized trial. Breast Cancer Res Treat. 2005;93(3):255-260.
15. Joseph E, Hyacinthe M, Lyman GH, et al. Evaluation of an intensive strategy for follow-up and surveillance of primary breast cancer. Ann Surg Oncol. 1998;5(6):522-528.
16. Panageas KS, Sima CS, Liberman L, Schrag D. Use of high technology imaging for surveillance of early stage breast cancer. Breast Cancer Res Treat. 2012;131(2):663-670.
17. McCarthy NJ, Swain SM. Tumor markers: should we or shouldn't we? Cancer J. 2001;7(3):175-177.
18. Perey L, Hayes DF, Tondini C, et al. Elevated CA125 levels in patients with metastatic breast carcinoma. Br J Cancer. 1990;62(4):668-670.
19. Molina R, Zanon G, Filella X, et al. Use of serial carcinoembryonic antigen and CA 15.3 assays in detecting relapses in breast cancer patients. Breast Cancer Res Treat. 1995;36(1):41-48.
20. Mariani L, Miceli R, Michilin S, Gion M. Serial determination of CEA and CA 15.3 in breast cancer follow-up: an assessment of their diagnostic accuracy for the detection of tumour recurrences. Biomarkers. 2009;14(2):130-136.
21. Kokko R, Holli K, Hakama M. Ca 15-3 in the follow-up of localised breast cancer: a prospective study. Eur J Cancer. 2002;38(9):1189-1193.
22. Chan DW, Beveridge RA, Muss H, et al. Use of Truquant BR radioim-munoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease. J Clin Oncol. 1997;15(6):2322-2328.
23. Hayes DF, Smerage J. Is there a role for circulating tumor cells in the management of breast cancer? Clin Cancer Res. 2008;14(12):3646-3650.
24. Lucci A, Hall CS, Lodhi AK, et al. Circulating tumour cells in non-meta-static breast cancer: a prospective study. Lancet Oncol. 2012;13(7):688-695.
25. Rack BK, Schindlbeck C, Andergassen U, et al. Use of circulating tumor cells (CTC) in peripheral blood of breast cancer patients before and after adjvuant chemotherapy to predict risk for relapse: The SUCCESS trial. J Clin Oncol. 2010;28(Suppl):abstract 1003.
26. Lu WL, Jansen L, Post WJ, et al. Impact on survival of early detection of isolated breast recurrences after the primary treatment for breast cancer: a meta-analysis. Breast Cancer Res Treat. 2009;114(3):403-412.
27. Kovner F, Merimsky O, Hareuveni M, Wigler N, Chaitchik S. Treatment of disease-negative but mucin-like carcinoma-associated antigen-positive breast cancer patients with tamoxifen: preliminary results of a prospective controlled randomized trial. Cancer Chemother Pharmacol. 1994;35(1):80-83.
28. Merimsky O, Kovner F, Inbar M, et al. Tamoxifen for disease-negative but MCA-positive breast cancer patients. Oncol Rep. 1997;4(4):843-847.
29. Nicolini A, Carpi A, Michelassi C, et al. "Tumour marker guided" salvage treatment prolongs survival of breast cancer patients: final report of a 7-year study. Biomed Pharmacother. 2003;57(10):452-459.
30. Nicolini A, Anselmi L, Michelassi C, Carpi A. Prolonged survival by "early" salvage treatment of breast cancer patients: a retrospective 6-year study. Br J Cancer. 1997;76(8):1106-1111.
31. Brenner DJ, Hall EJ. Computed tomography-an increasing source of radiation exposure. N Engl J Med. 2007;357(22):2277-2284.
32. Smith-Bindman R. Environmental causes of breast cancer and radiation from medical imaging: findings from the Institute of Medicine report. Arch Intern Med. 2012;172(13):1023-1027.
33. Colomer R, Ruibal A, Genolla J, et al. Circulating CA 15-3 levels in the postsurgical follow-up of breast cancer patients and in non-malignant diseases. Breast Cancer Res Treat. 1989;13(2):123-133.
34. Gulliford T, Opomu M, Wilson E, Hanham I, Epstein R. Popularity of less frequent follow up for breast cancer in randomised study: initial findings from the hotline study. British Med J. 1997;314(7075):174-177.
35. de Bock GH, Bonnema J, Zwaan RE, et al. Patient's needs and preferences in routine follow-up after treatment for breast cancer. Br J Cancer. 2004;90(6):1144-1150.
36. Hans-Joachim S, Dorit L, Petra S, et al. The reality in the surveillance of breast cancer survivors-results of a patient survey. Breast Cancer (Auckl). 2008;1:17-23.
37. Schapira DV. Breast cancer surveillance-a cost-effective strategy. Breast Cancer Res Treat. 1993;25(2):107-111.
38. Mille D, Roy T, Carrere MO, et al. Economic impact of harmonizing medical practices: compliance with clinical practice guidelines in the follow-up of breast cancer in a French Comprehensive Cancer Center. J Clin Oncol. 2000;18(8):1718-1724.
39. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-752.
40. Molina R, Barak V, van Dalen A, et al. Tumor markers in breast cancer-European Group on Tumor Markers recommendations. Tumour Biol. 2005;26(6):281-293.
41. De Vita VT. The relationship between tumor mass and resistance to chemotherapy. Implications for surgical adjuvant therapy of cancer. Cancer. 1983;51(7):1209-1220.
42. Skipper HE. Kinetics of mammary tumor cell growth and implications for therapy. Cancer. 1971;28(6):1479-1499
43. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687-1717.
44. Hortobagyi G. Can we cure limited metastatic breast cancer? J Clin Oncol. 2002;20(3):620-623.
45. Buzdar AU, Blumenschein GR, Montague ED, et al. Combined modality approach in breast cancer with isolated or multiple metastases. Am J Clin Oncol. 1984;7(1):45-50.
46. Ganz PA, Land SR, Antonio C, et al. Cancer survivorship research: the challenge of recruiting adult long term cancer survivors from a cooperative clinical trials group. J Cancer Surviv. 2009;3(3):137-147.
47. Rowland JH, Hewitt M, Ganz PA. Cancer survivorship: a new challenge in delivering quality cancer care. J Clin Oncol. 2006;24(32):5101-5104.